Diagnostyka

Diagnostyka EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Diagnostyka (DIA.WA) as of Nov 5, 2026 is 19.55. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 23.82 — a change of -17.91% (lower).

EV/FCF

19.55

YoY

-17.91%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Diagnostyka is 2025 19.55 . EV/FCF (Enterprise Value to Free Cash Flow) of Diagnostyka was 2024 23.82 . It decreases by -17.91% lower compared to the previous year.

The Diagnostyka EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2021
10.57 PLN
Jan 1, 2022
33.84 PLN
Jan 1, 2023
26.28 PLN
Jan 1, 2024
23.82 PLN
Jan 1, 2025
19.55 PLN
The Diagnostyka EV/FCF history
YEAREV/FCFYoY
19.55-17.91%
23.82-9.35%
26.28-22.35%
33.84+220.19%
10.57—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Diagnostyka Stock analysis

What does Diagnostyka do? Diagnostyka SA generates revenue through its network of 180 laboratories and 1,100 Sampling Labs across Poland, offering over 3,000 test types including hematology, infection diagnostics, allergology, and hormonal diagnostics. The company provides both routine and specialist laboratory services, with tests available with or without a physician's referral, catering to individual patients and healthcare providers. Its specialization in molecular biology, autoimmune diagnostics, and blood collection drives demand from private individuals seeking direct access to medical analysis without a doctor's prescription. The firm's revenue model relies on a comprehensive service chain from biological material collection and transportation to final analysis results, serving a broad customer base including patients, clinics, and hospitals. With a focus on accessible diagnostics, Diagnostyka SA expands its market reach through its extensive lab network, enabling widespread availability of medical testing services throughout Poland. The company's ability to deliver specialized tests like molecular biology and autoimmune diagnostics differentiates its offerings in the healthcare sector. Diagnostyka is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Diagnostyka stock

EV/FCF (Enterprise Value to Free Cash Flow) of Diagnostyka is 19.55 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Diagnostyka changed from 23.82 to 19.55, representing a -17.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Diagnostyka since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Diagnostyka with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Diagnostyka

All Key Metrics — Diagnostyka